Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.33 |
| ▸ | MAOA | P21397 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26685539 | 0.86 | — | — | |
| SCHEMBL24269649 | 0.86 | — | — | |
| SCHEMBL3968340 | 0.83 | GNAI3 (0.39) | MAOBMAOAALDH1A1MAPTPKM | |
| Hydrochloric Acid SCHEMBL3430097 | 0.81 | GNAI3 (0.42) | MAOBMAOAALDH1A1MAPTPKM | |
| SCHEMBL22691891 | 0.78 | MAOB (0.36) | MAOBMAOAALDH1A1MAPTPKM | |
| SCHEMBL3897207 | 0.78 | GPR119 (0.50) | ALDH1A1MAPTJAK2JAK1TYK2 | |
| SCHEMBL665735 | 0.78 | ALDH1A1 (0.33) | ALDH1A1MAPTPKMJAK2JAK1 | |
| SCHEMBL665736 | 0.78 | ACHE (0.43) | ALDH1A1POLB | |
| SCHEMBL7137154 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPKMLMNAPOLB | |
| SCHEMBL2576487 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPKMLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200109120-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-04-09 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2014062838-A2 | PKM2 MODULATORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2356114-A1 | AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054762-A1 | AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054762-A1 | AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766865-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | MAOB 3541/4885MAOA 3784/4885ALDH1A1 2333/4885 |
| US-10472328-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | MAOB 3541/4885MAOA 3784/4885ALDH1A1 2333/4885 |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | VHL, HIF1AN, HIF1A | MAOB 503/4885MAOA 785/4885ALDH1A1 297/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | MAOB 2166/4885MAOA 2289/4885ALDH1A1 2773/4885 |
| US-10207996-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | MAOB 3541/4885MAOA 3784/4885ALDH1A1 2333/4885 |
| US-20200109120-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | MAOB 3541/4885MAOA 3784/4885ALDH1A1 2333/4885 |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | MAOB 3541/4885MAOA 3784/4885ALDH1A1 2333/4885 |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | MAOB 3541/4885MAOA 3784/4885ALDH1A1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.